[go: up one dir, main page]

MXPA99011322A - Composicion que comprende [5-[4 -[2-(n- metil-n-2piridil) amino)etoxi] bencil] tiazolidino-2, 4-diona. - Google Patents

Composicion que comprende [5-[4 -[2-(n- metil-n-2piridil) amino)etoxi] bencil] tiazolidino-2, 4-diona.

Info

Publication number
MXPA99011322A
MXPA99011322A MXPA99011322A MX9911322A MXPA99011322A MX PA99011322 A MXPA99011322 A MX PA99011322A MX PA99011322 A MXPA99011322 A MX PA99011322A MX 9911322 A MX9911322 A MX 9911322A MX PA99011322 A MXPA99011322 A MX PA99011322A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
compound
composition
acceptable form
further characterized
Prior art date
Application number
MXPA99011322A
Other languages
English (en)
Spanish (es)
Inventor
Roger Granett Jeffrey
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MXPA99011322A publication Critical patent/MXPA99011322A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA99011322A 1997-06-05 1998-06-02 Composicion que comprende [5-[4 -[2-(n- metil-n-2piridil) amino)etoxi] bencil] tiazolidino-2, 4-diona. MXPA99011322A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (fr) 1997-06-05 1998-06-02 Composition renfermant de la 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
MXPA99011322A true MXPA99011322A (es) 2004-12-02

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99011322A MXPA99011322A (es) 1997-06-05 1998-06-02 Composicion que comprende [5-[4 -[2-(n- metil-n-2piridil) amino)etoxi] bencil] tiazolidino-2, 4-diona.

Country Status (29)

Country Link
EP (1) EP0998284A1 (fr)
JP (1) JP2001521553A (fr)
KR (1) KR20010013410A (fr)
CN (3) CN1526391A (fr)
AP (1) AP1214A (fr)
AR (2) AR015120A1 (fr)
AU (1) AU8215098A (fr)
BG (1) BG104048A (fr)
BR (1) BR9810405A (fr)
CA (2) CA2333352A1 (fr)
CO (1) CO4940400A1 (fr)
DZ (1) DZ2510A1 (fr)
EA (1) EA002384B1 (fr)
GB (1) GB9711683D0 (fr)
HU (1) HUP0004070A3 (fr)
ID (1) ID24264A (fr)
IL (1) IL133074A0 (fr)
MX (1) MXPA99011322A (fr)
NO (2) NO995938L (fr)
NZ (2) NZ523725A (fr)
OA (1) OA11306A (fr)
PE (1) PE78899A1 (fr)
PL (1) PL337201A1 (fr)
SK (1) SK164899A3 (fr)
TR (2) TR199902963T2 (fr)
TW (1) TW570797B (fr)
UY (1) UY25032A1 (fr)
WO (1) WO1998055122A1 (fr)
ZA (2) ZA984826B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
MXPA01010821A (es) * 1999-04-23 2003-09-04 Smithkline Beecham Plc Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
WO2015008234A1 (fr) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Composés hétécycliques bicycliques utilisés en tant que modulateurs des ror-gamma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CA2182986A1 (fr) * 1994-02-10 1995-08-17 Smithkline Beecham P.L.C. Utilisation de sensibilisateurs a l'insuline dans le traitement de l'insuffisance renale
WO1997005875A2 (fr) * 1995-08-10 1997-02-20 Warner-Lambert Company Procede permettant de reduire la quantite d'insuline exogene administree a un patient souffrant de diabete sucre non-insulinodependant
WO1997018811A1 (fr) * 1995-11-17 1997-05-29 Warner-Lambert Company Procede de traitement de dystrophie myotonique
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (fr) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Nouveau traitement contre la resistance a la leptine

Also Published As

Publication number Publication date
CN1259050A (zh) 2000-07-05
KR20010013410A (fr) 2001-02-26
NO995938L (no) 2000-02-02
ZA9811572B (en) 1999-07-22
AU8215098A (en) 1998-12-21
SK164899A3 (en) 2000-11-07
HUP0004070A3 (en) 2002-03-28
NO20040738L (no) 2000-02-02
OA11306A (en) 2003-10-22
CN1526391A (zh) 2004-09-08
IL133074A0 (en) 2001-03-19
AR008198A1 (es) 1999-12-29
WO1998055122A1 (fr) 1998-12-10
BR9810405A (pt) 2000-08-29
JP2001521553A (ja) 2001-11-06
DZ2510A1 (fr) 2003-01-25
EA199901116A1 (ru) 2000-06-26
ZA984826B (en) 1999-08-03
AP1214A (en) 2003-10-08
PE78899A1 (es) 1999-10-22
TW570797B (en) 2004-01-11
CN1112926C (zh) 2003-07-02
CA2292629C (fr) 2004-01-06
CA2333352A1 (fr) 1998-12-10
PL337201A1 (en) 2000-08-14
CO4940400A1 (es) 2000-07-24
ID24264A (id) 2000-07-13
NZ513922A (en) 2001-09-28
NO995938D0 (no) 1999-12-03
TR200002790T2 (tr) 2001-11-21
CA2292629A1 (fr) 1998-12-10
GB9711683D0 (en) 1997-08-06
AR015120A1 (es) 2001-04-18
BG104048A (bg) 2000-07-31
HUP0004070A2 (hu) 2002-02-28
EP0998284A1 (fr) 2000-05-10
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
UY25032A1 (es) 1998-11-26
CN1430959A (zh) 2003-07-23
AP9901696A0 (en) 1999-12-31
EA002384B1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
EP1292300B1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyl et d'autres agents antidiabetiques pour traiter le diabete sucre
CZ298469B6 (cs) Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
MXPA99011322A (es) Composicion que comprende [5-[4 -[2-(n- metil-n-2piridil) amino)etoxi] bencil] tiazolidino-2, 4-diona.
SK179399A3 (en) Use of insulin sensitiser and an insulin
US20020177612A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP0999845B1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de sulfonyluree
EP0998291B1 (fr) Traitement du diabete avec du thiazolidinedione et de la sulfonyluree
US20020028768A1 (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
CZ432299A3 (cs) Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
HK1028200B (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
CZ9904579A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
MXPA99012091A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1029272B (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HU226960B1 (en) Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes
MXPA99012078A (en) Treatment of diabetes with thiazolidinedione and metformin